ID   IMR-32
AC   CVCL_0346
SY   IMR 32; IMR32; Institute for Medical Research-32; GM03320; GM3320C; GM03320D; AG03320; AG3320
DR   BTO; BTO:0000934
DR   CLO; CLO_0006948
DR   CLO; CLO_0016777
DR   EFO; EFO_0001195
DR   MCCL; MCC:0000242
DR   CLDB; cl2878
DR   CLDB; cl2879
DR   CLDB; cl2880
DR   CLDB; cl2881
DR   CLDB; cl2882
DR   CLDB; cl2883
DR   CLDB; cl2885
DR   CLDB; cl2886
DR   CLDB; cl2887
DR   CLDB; cl2888
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CCL-127
DR   BCRC; 60014
DR   BCRJ; 0377
DR   BioGRID_ORCS_Cell_line; 637
DR   BioSample; SAMN00808348
DR   BioSample; SAMN03472412
DR   BioSample; SAMN03473082
DR   BioSample; SAMN10988103
DR   cancercelllines; CVCL_0346
DR   CCRID; 1101HUM-PUMC000282
DR   CCRID; 3101HUMTCHu145
DR   CCRID; 4201HUM-CCTCC00107
DR   Cell_Model_Passport; SIDM00226
DR   CGH-DB; 78-1
DR   CGH-DB; 9095-4
DR   ChEMBL-Cells; CHEMBL3307656
DR   ChEMBL-Targets; CHEMBL614585
DR   CLS; 300148
DR   Coriell; AG03320
DR   Coriell; GM03320
DR   Cosmic; 688067
DR   Cosmic; 759892
DR   Cosmic; 801746
DR   Cosmic; 920239
DR   Cosmic; 922658
DR   Cosmic; 947702
DR   Cosmic; 1019944
DR   Cosmic; 1037352
DR   Cosmic; 1099149
DR   Cosmic; 1109111
DR   Cosmic; 1237544
DR   Cosmic; 1518066
DR   Cosmic; 1526626
DR   Cosmic; 2058113
DR   Cosmic; 2131590
DR   Cosmic; 2301580
DR   Cosmic; 2393630
DR   Cosmic; 2485944
DR   DepMap; ACH-000310
DR   DSMZ; ACC-165
DR   DSMZCellDive; ACC-165
DR   ECACC; 86041809
DR   EGA; EGAS00001000610
DR   GEO; GSM453632
DR   GEO; GSM563362
DR   GEO; GSM692859
DR   GEO; GSM887162
DR   GEO; GSM888234
DR   GEO; GSM1366406
DR   GEO; GSM1669934
DR   GEO; GSM2371237
DR   GEO; GSM2394364
DR   IARC_TP53; 23585
DR   ICLC; HTL96021
DR   JCRB; IFO50283
DR   KCB; KCB 2011100YJ
DR   KCLB; 10127
DR   LiGeA; CCLE_016
DR   Lonza; 971
DR   PharmacoDB; IMR32_659_2019
DR   PRIDE; PXD000589
DR   Progenetix; CVCL_0346
DR   PubChem_Cell_line; CVCL_0346
DR   RCB; RCB1895
DR   TKG; TKG 0207
DR   Wikidata; Q54897618
RX   CelloPub=CLPUB00387;
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1007/978-1-4757-1647-4_13;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=62055;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=922665;
RX   PubMed=2535691;
RX   PubMed=3518877;
RX   PubMed=3698005;
RX   PubMed=5459762;
RX   PubMed=6401685;
RX   PubMed=6888561;
RX   PubMed=6935474;
RX   PubMed=7037175;
RX   PubMed=7139592;
RX   PubMed=7253718;
RX   PubMed=7459858;
RX   PubMed=7838528;
RX   PubMed=8221663;
RX   PubMed=8490657;
RX   PubMed=8665486;
RX   PubMed=9201287;
RX   PubMed=9283597;
RX   PubMed=9516836;
RX   PubMed=11550280;
RX   PubMed=11668190;
RX   PubMed=12210830;
RX   PubMed=12702577;
RX   PubMed=15390183;
RX   PubMed=15892104;
RX   PubMed=16524757;
RX   PubMed=16822308;
RX   PubMed=17974978;
RX   PubMed=20655465;
RX   PubMed=22213050;
RX   PubMed=22460905;
RX   PubMed=24466371;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25894527;
RX   PubMed=26589293;
RX   PubMed=28350380;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31581737;
RX   PubMed=33460449;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Characteristics: Neuroblastic type (N-type).
CC   Doubling time: 48 hours (PubMed=5459762); ~20 hours (ATCC=CCL-127); ~40-50 hours (DSMZ=ACC-165).
CC   HLA typing: A*24:02,24:02; B*07:05,07:05; C*05:01,12:03 (PubMed=26589293).
CC   Omics: Array-based CGH.
CC   Omics: Cell surface proteome.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.56%; East Asian, North=1.01%; East Asian, South=0%; South Asian=3.99%; European, North=73.7%; European, South=20.72% (PubMed=30894373).
CC   Misspelling: IMR-92; Note=Occasionally.
CC   Misspelling: IRM-32; Note=Occasionally.
CC   Discontinued: Coriell; AG03320; probable.
CC   Discontinued: RCB; RCB1895; true.
CC   Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
ST   Source(s): ATCC; CCRID; CLS; COG; DSMZ; IZSLER; JCRB; KCLB; PubMed=25877200; PubMed=31581737; PubMed=33460449; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9
ST   D16S539: 8 (ATCC; CCRID; COG; DSMZ; IZSLER; JCRB; PubMed=25877200; PubMed=31581737; PubMed=33460449; RCB; TKG)
ST   D16S539: 8,10 (CLS)
ST   D18S51: 12,15
ST   D19S433: 14,15
ST   D21S11: 30,31
ST   D2S1338: 23,24
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 13
ST   FGA: 21,24
ST   Penta D: 11,12
ST   Penta E: 7,15
ST   TH01: 7,9.3 (CCRID; CLS; COG; DSMZ; IZSLER; JCRB_IFO50283; KCLB; PubMed=25877200; PubMed=31581737; PubMed=33460449; RCB; TKG)
ST   TH01: 7,10 (JCRB_JCRB9050)
ST   TPOX: 11
ST   vWA: 15
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   1Y1M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 45
RX   CelloPub=CLPUB00387;
RA   Coriell L.L., Greene A.E., Mulivor R.A.;
RT   "The human genetic mutant cell repository: list of genetic variants,
RT   chromosomal aberrations and normal cell cultures submitted to the
RT   repository. 7th edition. October 1980.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 80-2011; pp.1-254; National Institutes of Health; Bethesda (1980).
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
RX   DOI=10.1007/978-1-4757-1647-4_13;
RA   Biedler J.L.;
RT   "Chromosome abnormalities in human tumor cells in culture.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975).
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
RX   PubMed=62055; DOI=10.1093/jnci/57.3.683;
RA   Biedler J.L., Spengler B.A.;
RT   "A novel chromosome abnormality in human neuroblastoma and
RT   antifolate-resistant Chinese hamster cell lives in culture.";
RL   J. Natl. Cancer Inst. 57:683-695(1976).
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
RX   PubMed=922665; DOI=10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1;
RA   Brodeur G.M., Sekhon G., Goldstein M.N.;
RT   "Chromosomal aberrations in human neuroblastomas.";
RL   Cancer 40:2256-2263(1977).
RX   PubMed=2535691;
RA   Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.;
RT   "Phenotypic diversification in human neuroblastoma cells: expression
RT   of distinct neural crest lineages.";
RL   Cancer Res. 49:219-225(1989).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=3698005;
RA   Bregman M.D., Funk C., Fukushima M.;
RT   "Inhibition of human melanoma growth by prostaglandin A, D, and J
RT   analogues.";
RL   Cancer Res. 46:2740-2744(1986).
RX   PubMed=5459762;
RA   Tumilowicz J.J., Nichols W.W., Cholon J.J., Greene A.E.;
RT   "Definition of a continuous human cell line derived from
RT   neuroblastoma.";
RL   Cancer Res. 30:2110-2118(1970).
RX   PubMed=6401685; DOI=10.1007/BF02617989;
RA   Halton D.M., Peterson W.D. Jr., Hukku B.;
RT   "Cell culture quality control by rapid isoenzymatic
RT   characterization.";
RL   In Vitro 19:16-24(1983).
RX   PubMed=6888561; DOI=10.1038/305245a0;
RA   Schwab M., Alitalo K., Klempnauer K.-H., Varmus H.E., Bishop J.M.,
RA   Gilbert F., Brodeur G.M., Goldstein M.N., Trent J.M.;
RT   "Amplified DNA with limited homology to myc cellular oncogene is
RT   shared by human neuroblastoma cell lines and a neuroblastoma tumour.";
RL   Nature 305:245-248(1983).
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
RX   PubMed=7037175;
RA   Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.;
RT   "Selective toxicity of 6-hydroxydopamine and ascorbate for human
RT   neuroblastoma in vitro: a model for clearing marrow prior to
RT   autologous transplant.";
RL   Cancer Res. 42:1331-1336(1982).
RX   PubMed=7139592; DOI=10.1016/0165-4608(82)90105-4;
RA   Gilbert F., Balaban G.B., Moorhead P.S., Bianchi D., Schlesinger H.R.;
RT   "Abnormalities of chromosome 1p in human neuroblastoma tumors and cell
RT   lines.";
RL   Cancer Genet. Cytogenet. 7:33-42(1982).
RX   PubMed=7253718; DOI=10.1016/0047-6374(81)90027-0;
RA   Das N.K., Murphy D.G.;
RT   "The National Institute on Aging repository cell cultures.";
RL   Mech. Ageing Dev. 16:1-17(1981).
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
RX   PubMed=7838528;
RA   Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A.,
RA   Speleman F., Versteeg R.;
RT   "Deletion mapping in neuroblastoma cell lines suggests two distinct
RT   tumor suppressor genes in the 1p35-36 region, only one of which is
RT   associated with N-myc amplification.";
RL   Oncogene 10:291-297(1995).
RX   PubMed=8221663;
RA   Komuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y.,
RA   Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., Tsuchida Y.;
RT   "Mutations of the p53 gene are involved in Ewing's sarcomas but not in
RT   neuroblastomas.";
RL   Cancer Res. 53:5284-5288(1993).
RX   PubMed=8490657; DOI=10.1038/ng0193-62;
RA   The I., Murthy A.E., Hannigan G.E., Jacoby L.B., Menon A.G.,
RA   Gusella J.F., Bernards A.;
RT   "Neurofibromatosis type 1 gene mutations in neuroblastoma.";
RL   Nat. Genet. 3:62-66(1993).
RX   PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4;
RA   Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.;
RT   "The p16 and p18 tumor suppressor genes in neuroblastoma: implications
RT   for drug resistance.";
RL   Cancer Lett. 104:183-192(1996).
RX   PubMed=9201287;
RA   Cinatl J. Jr., Hernaiz Driever P., Cinatl J., Ruckert D.G.,
RA   Gumbel H.O., Rabenau H.F., Kornhuber B., Doerr H.-W.;
RT   "Increased efficacy of aphidicolin killing of human neuroblastoma
RT   cells in vitro by encapsulation in liposomes.";
RL   Neoplasma 44:91-95(1997).
RX   PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7;
RA   Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R.,
RA   De Paepe A., Cremer T., Speleman F.;
RT   "Comparative genomic hybridization analysis of human neuroblastomas:
RT   detection of distal 1p deletions and further molecular genetic
RT   characterization of neuroblastoma cell lines.";
RL   Cancer Genet. Cytogenet. 97:135-142(1997).
RX   PubMed=9516836; DOI=10.1016/S0959-8049(97)00319-5;
RA   Van Roy N., Laureys G., Van Gele M., Opdenakker G., Miura R.,
RA   van der Drift P., Chan A., Versteeg R., Speleman F.;
RT   "Analysis of 1;17 translocation breakpoints in neuroblastoma:
RT   implications for mapping of neuroblastoma genes.";
RL   Eur. J. Cancer 33:1974-1978(1997).
RX   PubMed=11550280; DOI=10.1002/gcc.1174;
RA   Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B.,
RA   Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.;
RT   "Combined M-FISH and CGH analysis allows comprehensive description of
RT   genetic alterations in neuroblastoma cell lines.";
RL   Genes Chromosomes Cancer 32:126-135(2001).
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
RX   PubMed=12210830; DOI=10.1002/jnr.10330;
RA   Yoshida S., Narita T., Taga T., Ohta S., Takeuchi Y.;
RT   "Malignant rhabdoid tumor shows incomplete neural characteristics as
RT   revealed by expression of SNARE complex.";
RL   J. Neurosci. Res. 69:642-652(2002).
RX   PubMed=12702577;
RA   Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A.,
RA   Sugimoto T., Inazawa J.;
RT   "PPM1D is a potential target for 17q gain in neuroblastoma.";
RL   Cancer Res. 63:1876-1883(2003).
RX   PubMed=15390183; DOI=10.1002/gcc.20096;
RA   Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.;
RT   "Expression profiles and clinical relationships of ID2, CDKN1B, and
RT   CDKN2A in primary neuroblastoma.";
RL   Genes Chromosomes Cancer 41:297-308(2004).
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
RX   PubMed=16524757; DOI=10.1016/j.biocel.2006.01.007;
RA   Fry D.G., Dayton B.D., Brodjian S., Ogiela C., Sidorowicz H.,
RA   Frost L.J., McNally T., Reilly R.M., Collins C.A.;
RT   "Characterization of a neuronal cell line expressing native human
RT   melanin-concentrating hormone receptor 1 (MCHR1).";
RL   Int. J. Biochem. Cell Biol. 38:1290-1299(2006).
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
RX   PubMed=17974978; DOI=10.1158/0008-5472.CAN-06-4345;
RA   Xue C.-Y., Haber M., Flemming C., Marshall G.M., Lock R.B.,
RA   MacKenzie K.L., Gurova K.V., Norris M.D., Gudkov A.V.;
RT   "p53 determines multidrug sensitivity of childhood neuroblastoma.";
RL   Cancer Res. 67:10351-10360(2007).
RX   PubMed=20655465; DOI=10.1016/j.cell.2010.06.004;
RA   Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N.,
RA   Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C.,
RA   Messiaen L.M., Versteeg R., Bernards R.;
RT   "NF1 is a tumor suppressor in neuroblastoma that determines retinoic
RT   acid response and disease outcome.";
RL   Cell 142:218-229(2010).
RX   PubMed=22213050; DOI=10.1002/ijc.27415;
RA   Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J.,
RA   Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.;
RT   "PEA15 impairs cell migration and correlates with clinical features
RT   predicting good prognosis in neuroblastoma.";
RL   Int. J. Cancer 131:1556-1568(2012).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31581737; DOI=10.3390/cells8101194;
RA   Povey J.F., Saintas E., Aderemi A.V., Rothweiler F., Zehner R.,
RA   Dirks W.G., Cinatl J. Jr., Racher A.J., Wass M.N., Smales C.M.,
RA   Michaelis M.;
RT   "Intact-cell MALDI-ToF mass spectrometry for the authentication of
RT   drug-adapted cancer cell lines.";
RL   Cells 8:1194.1-1194.12(2019).
RX   PubMed=33460449; DOI=10.1002/ijc.33474;
RA   Dirks W.G., Capes-Davis A., Eberth S., Fahnrich S., Wilting J.,
RA   Nagel S., Steenpass L., Becker J.;
RT   "Cross-contamination meets misclassification: awakening of CHP-100
RT   from sleeping beauty sleep -- a reviewed model for Ewing's sarcoma.";
RL   Int. J. Cancer 148:2608-2613(2021).